139 related articles for article (PubMed ID: 20375091)
1. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
2. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
3. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
4. Rosiglitazone and implications for pharmacovigilance.
Kazi D
BMJ; 2007 Jun; 334(7606):1233-4. PubMed ID: 17569897
[TBL] [Abstract][Full Text] [Related]
5. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
6. Drug safety. Heart attack risk overshadows a popular diabetes therapy.
Couzin J
Science; 2007 Jun; 316(5831):1550-1. PubMed ID: 17569830
[No Abstract] [Full Text] [Related]
7. Rosiglitazone and cardiovascular risk.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
[No Abstract] [Full Text] [Related]
8. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N
Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
[No Abstract] [Full Text] [Related]
9. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
10. Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Grant PJ
Diab Vasc Dis Res; 2007 Jun; 4(2):75-6. PubMed ID: 17654437
[No Abstract] [Full Text] [Related]
11. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
12. Straight talk from... Bruce Psaty. Interviewed by Emma Marris.
Psaty B
Nat Med; 2007 Jul; 13(7):767. PubMed ID: 17618256
[No Abstract] [Full Text] [Related]
13. Faster publication isn't always better.
Fuster V; Farkouh ME
Nat Clin Pract Cardiovasc Med; 2007 Jul; 4(7):345. PubMed ID: 17589426
[No Abstract] [Full Text] [Related]
14. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
15. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
16. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
17. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
18. The ethics of pharmaceutical industry gift-giving: the role of a professional association.
Morin K; Morse LJ
Am J Bioeth; 2003; 3(3):54-5. PubMed ID: 14594494
[No Abstract] [Full Text] [Related]
19. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review.
Wang AT; McCoy CP; Murad MH; Montori VM
BMJ; 2010 Mar; 340():c1344. PubMed ID: 20299696
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
McGuire DK
Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
[No Abstract] [Full Text] [Related]
[Next] [New Search]